Differences in biocompatibility of microneedles from cyclic olefin polymers with human endothelial and epithelial skin cells by Schossleitner, Klaudia et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Differences in biocompatibility of microneedles from cyclic olefin
polymers with human endothelial and epithelial skin cells
Author(s) Schossleitner, Klaudia; O'Mahony, Conor; Brandstätter, Stefan;
Haslinger, Michael J.; Demuth, Sabrina; Fechtig, Daniel; Petzelbauer,
Peter
Publication date 2018-11-19
Original citation Schossleitner, K., O'Mahony, C., Brandstätter, S., Haslinger, M.J.,
Demuth, S., Fechtig, D. and Petzelbauer, P., 2019. Differences in
biocompatibility of microneedles from cyclic olefin polymers with
human endothelial and epithelial skin cells. Journal of Biomedical
Materials Research Part A, 107(3), 505-512. DOI:10.1002/jbm.a.36565





Access to the full text of the published version may require a
subscription.
Rights © 2018 The Authors. Journal of Biomedical Materials Research Part
A published by Wiley Periodicals, Inc. This is an open access article
under the terms of the Creative Commons Attribution‐
NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly






Differences in biocompatibility of microneedles from cyclic olefin
polymers with human endothelial and epithelial skin cells
Klaudia Schossleitner ,1 Conor O’Mahony,2 Stefan Brandstätter,3 Michael J. Haslinger,4
Sabrina Demuth,1 Daniel Fechtig,4 Peter Petzelbauer1
1Skin and Endothelium Research Division, Department of Dermatology, Medical University Vienna, Vienna, Austria
2Tyndall National Institute, University College Cork, Cork, T12 R5CP, Ireland
3Stratec Consumables GmbH, Anif, Austria
4Functional Surfaces and Nanostructures, Profactor GmbH, Steyr-Gleink, Austria
Received 10 August 2018; revised 20 September 2018; accepted 28 September 2018
Published online 19 November 2018 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/jbm.a.36565
Abstract: Microneedles are promising devices for transdermal
delivery and diagnostic applications, due to their minimally
invasive and painless nature of application. However, so far,
applications are limited to small scale research projects. Mate-
rial selection and production for larger projects remain a chal-
lenge. In vitro testing using human cell culture could bridge
the gap between cost effective screening of suitable materials
and concerns for safety and ethics. In this study, materials
were tested for effects on viability and morphology of human
endothelial cells and keratinocytes. In addition, materials were
assessed for their potential to influence cellular differentiation
and barrier formation. Elution-based testing of inflammatory
markers revealed no negative effects in all applied tests,
whereas the assessment of differentiation markers on cells in
direct contact with the material showed differences and
allowed the selection of candidate materials for future medical
device applications. This study illustrates that elution-based
biocompatibility testing can paint an incomplete picture.
Advanced staining techniques and cell types specific for the
application of the medical device improve material selection to
reduce and replace animal testing at an early stage in the
development process. © 2018 The Authors. journal Of Biomedical
Materials Research Part A Published By Wiley Periodicals, Inc. J
Biomed Mater Res Part A: 107A: 505–512, 2019.
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INTRODUCTION
Microneedle-based transdermal drug delivery is highly attrac-
tive due to its needle-free nature and potential for self-adminis-
tration, with corresponding benefits in increased patient
compliance, reduced clinical time, elimination of needle-stick
injuries, and sharps waste.1–4 Microneedle-based devices have
also shown significant potential in transdermal diagnostics5:
electrodes may be used to detect biopotential signals such as
ECG or EEG without the use of electrolytic gels or skin prepara-
tion, functionalised for applications in electrochemical diagnos-
tics, or used to withdraw fluids for biomarker analysis.6–8
A microneedle is a short, sharp, spike-like structure, gen-
erally less than 1 mm in length, and is often provided in
arrays that may number anything up to several hundred per
square centimeter and that can penetrate the epidermal
layer of the skin. Although microneedles were originally fab-
ricated using techniques borrowed from the semiconductor
industry, injection molding has emerged as a viable alterna-
tive for their manufacture, especially as technical advances
have facilitated the accurate reproduction of the microscale
features associated with microneedles.9,10 Furthermore,
injection molding is a low-cost, high-throughput process that
has traditionally been compliant with medical device regula-
tions, materials and manufacturing procedures.
Cyclic olefin polymers (COPs) have low viscosity, good
mechanical strength, high chemical resistance, and low water
absorption. COPs have been processed in a variety of ways
to create biomedical microdevices,11 and are also a candi-
date for injection molding of microneedle arrays.12,13 How-
ever, the different compositions and monomers that make
up commercially available medical grade polymers have
raised questions about biocompatibility testing of these
materials.14 Different additives have already been shown to
have an effect on cytotoxicity and inflammation.15
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In this article, we show that different COP materials have
varying degrees of biocompatibility with human skin cell types.
We have found that these differences are not obvious from stan-
dard cytotoxicity testing methods as described in USP <87>16
and EU ISO 10993-5,17 but can be shown by the assessment of
inflammation and differentiation markers in human cells in vitro.
New cell culture based methods could give detailed information
about human biology and could reduce and replace animal test-
ing in rodents during early phases of product development.
MATERIALS AND METHODS
Polymer materials
A selection of COP granulate resins for medical applications
was purchased from Zeon specialty materials. Tested materials
were Zeonor 1020R (COP 1), Zeonex 690R (COP 2), and Zeo-
nex 5000 (COP 3) (Zeon, San Jose, CA). All materials had been
tested in the MEM-Elution test previously and were labeled
suitable for medical applications by the manufacturer.
Microneedle fabrication
Silicon microneedle templates, consisting of 100 mm diameter
wafers, were produced by the Tyndall National Institute using
the potassium hydroxide wet process described previously.6
These wafers were covered in microneedles measuring 500 μm
tall at a pitch of 1.725 mm. As a result of the wet etching process,
microneedles were shaped like octagonal pyramids with a side-
wall angle of 71 . Needle templates were then copied at Profactor
GmbH (Steyr, Austria) to obtain a negative shim (i.e., featuring
microcavities instead of microneedles). Shims were then
mounted in a mold and used for injection molding with COP
materials at STRATEC Consumables GmbH (Anif, Austria).
Cell culture
Human umbilical vein endothelial cells (HUVEC) were isolated
from human umbilical cords. The use of human umbilical cords
for the isolation of HUVECs has been approved by the Ethics Com-
mittee of the Medical University of Vienna (EK no. 1123/2009
renewed as 009/06/2018). Umbilical veins were washed in PBS
without Ca2+ and Mg2+ (Lonza, Basel, Switzerland) and incubated
with dispase (Corning, Bedford, MA) for 10 min at 37C. Endothe-
lial cells were flushed from the cord with HBSS (Lonza, Verviers,
Belgium), centrifuged and cultivated on tissue culture plastic
(Corning, NY) coated with 1% gelatine (Sigma, St. Louis, MO) in
medium M199 (Sigma, St. Louis, MO) containing 20% FCS (Gibco,
Grand Island, NY), and endothelial cell growth supplement
(Lonza, Verviers, Belgium) at 37C and 5% CO2. Human keratino-
cyte cell line HaCaT was kindly provided by Michael Mildner,
Medical University Vienna. Keratinocytes were cultured in serum
free keratinocyte growth medium (Lonza, Verviers, Belgium) at
37C and 5% CO2. Cells were passaged at 75%–90% confluency.
Medium eluate preparation of COPs
COP material granules or manufactured microneedle arrays
were weighed and transferred to sterile 6-well plates
(Corning, NY). Materials were covered with 1 mL M199
medium or keratinocyte medium per 0.2 g material and
incubated at 37C for 24 hours. Medium eluates were recov-
ered from the plate and used for subsequent experiments.
Morphology and viability assays
Cells were seeded to 96-well plates and grown to confluence
in endothelial growth media. Upon confluence growth
medium was replaced by prepared supernatants or control
medium with or without 0.1% H2O2 as control and cells
were incubated for 6 hours, 24 hours, or up to 14 days. At
respective time points, cell morphology was imaged with an
Axiovert40 microscope (Carl Zeiss, Germany). For assessing
cell viability, cells were incubated with 2 μM CalceinAM and
4 μM EthD-1 (Life technologies, Eugene, OR) for 15 min at
37C. Cells were imaged with the Axiovert40. For metabolic
activity, cells were incubated with MTS reagent (Promega,
Madison, WI) for 1 hour at 37C. Absorbance of the superna-
tant was measured at 490 nm in a Tristar LB941 microplate
reader (Berthold Technologies, Germany).
Flow cytometry
Primary antibodies: E-Selectin-FITC (BD Biosciences, NY), ICAM-
1-PE (BD Biosciences) and HLA-A/B/C-PECy5 (BD Biosciences).
For testing of material eluates, cells were seeded in
24-well plates and grown to confluence. Upon confluence the
endothelial or keratinocyte medium was replaced with the
respective material eluates or control medium with or with-
out 10 ng/mL TNFα (endothelial cells) or 50 ng/mL TNFα
and IFNγ (keratinocytes) as control. Cells were incubated for
6 hours, 24 hours or 48 hours. At respective time point, cells
were detached with PBS without Ca2+ or Mg2+ and washed
twice. Antibodies were added in PBS with 1% BSA for 30 min
on ice. Cells were washed again and measured in a Cytoflex
flow cytometer (Beckman Coulter, Indianapolis, IN).
Immunofluorescence
Primary antibodies: E-cadherin-488 (Biolegend, San Diego),
Vimentin-NL557 (R&D Systems, Minneapolis, MN).
Keratinocytes were seeded in direct contact with the
microneedle materials and cultured for 7 or 14 days. Sam-
ples were fixed in 4% neutral buffered formaldehyde, per-
meabilized with 0.5% Triton X-100 and stained with directly
labeled E-cadherin and vimentin antibodies. Images were
taken with a LSM700 confocal microscope (Zeiss).
Statistical analysis
Data were analyzed with SPSS v. 22 software package (IBM
Corp., Armonk, NY). Statistical significance was assessed by
ANOVA. A p-value below or equal to .05 was considered sta-
tistically significant.
RESULTS
No cytotoxicity of tested materials was detected with
the standard elution method
Arrays of sharp microneedle structures were manufactured by
injection molding of cyclic olefin polymers (COP) (Fig. 1). Stan-
dard injection molding as well as injection compression mold-
ing techniques were investigated and two different heating
methods (isothermal and variothermal) were utilized for pro-
cess optimization. In addition, some mold parts were modified
to be able to mount the shim into an existing mold. After exten-
sive process tests a reliable isothermal molding process without
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compression was found. The microneedle arrays were easily
demouldable and sharp needle tips were achieved.
Samples of pelleted COP material and finished micronee-
dle devices were tested for biocompatibility. In agreement
with supplier data, co-incubation of human umbilical vein
endothelial cells (HUVEC) with pelleted polymer material
eluates before microneedle manufacturing did not exert any
cytotoxic effect as seen from morphology or viability of
human cells (Fig. 2). All materials showed less than 20% dif-
ference from medium control samples as required by
FIGURE 1. Production process and finished microneedle arrays made from COP. A schematic layout of the mass-fabrication process used for the
microneedle devices in this study can be seen in (A). Brightfield microscopic images of microneedle arrays in silicon are seen in (B). (C) Shows a
brightfield microscopic image of an exemplary microneedle array in COP and a detailed electron microscopic image of an exemplary needle in
COP. Scale bars equal 200 μm.
FIGURE 2. Unchanged cell morphology and viability with incubation of COP raw material eluates. Brightfield images are shown of human umbilical
vein endothelial cells (HUVEC) incubated with or without pelleted COP material for 24 hours. Viable HUVEC were labeled with CalceinAM (LIVE,
green), dead cells were labeled with EthD-1 (DEAD, red). Scale bar represents 100 μm.
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standard cytotoxicity test methods.16,17 To test for cytotoxic-
ity of the finished microneedles after the manufacturing pro-
cess, eluates were prepared from the finished microneedle
arrays and incubated with two different human cell types
found in the skin, vascular endothelial cells, and keratino-
cytes. Morphology and viability [Fig. 3(A,B)] as well as meta-
bolic activity [Fig. 3(C)] of human cells incubated with
microneedle eluates did not differ from cells incubated with
FIGURE 3. Eluates from COP materials did not elicit cytotoxicity in human endothelial or epithelial cells. Cells were incubated with eluates from indi-
cated materials, medium control or 0.1% H2O2 for 24 hours. Viable cells were stained with CalceinAM (green), apoptotic cells were stained with
EthD-1 (red). Scale bar equals 100 μm. Apoptotic endothelial cells detach and leave a cell free area. Cell free area per high power field was quanti-
fied and summarized in (A). Apoptotic epithelial cells adhere to the material surface. Dead cell count per high power field was quantified and sum-
marized in (B); mean+/-SD n = 6. Metabolic activity of human endothelial and epithelial cells in response to cyclic olefin polymer eluates is
quantified in (C). Cells were incubated with eluates from indicated materials, medium control, TNFα, IFNγ or 0.1% H2O2 for 24 hours. Metabolic
activity was determined by the conversion of the tetrazolium compound MTS and quantification of absorbance at 490 nm. Mean +/-SD n = 10.
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control cell culture medium. Likewise, the viability and meta-
bolic activity of keratinocytes in direct contact with COPs for
up to 7 days was not different from medium controls [Sup-
porting Information Fig. S1(A,B)]. Thus, human endothelial
cells and keratinocytes showed no cytotoxicity of COP mate-
rials according to standard methods commonly used for
fibroblast cell lines.
Absence of inflammatory marker upregulation in human
endothelial and epithelial cells
To get additional information about the status of endothelial
and epithelial cells the inflammation markers E-Selectin,
ICAM-1 and HLA-A/B/C were analyzed by flow cytometry.
Endothelial and epithelial cells displayed no upregulation of
inflammation-specific markers after incubation with eluates
from COPs [Fig. 4(A,B), respectively] or after direct contact
(Supporting Information Fig. S1(C)]. Furthermore, prolonged
incubation of endothelial cells with COP materials for 7 days
did not lead to upregulation of inflammation markers (data
not shown). Thus, no negative effects of additives leaching
from manufactured microneedles were seen in culture with
human cells.
Different COP materials showed an effect on
keratinocyte differentiation markers
To further characterize the interaction of COP material with
human skin cells, keratinocytes were seeded in direct con-
tact with the finished microneedle arrays. Differences in ker-
atinocyte morphology were noted in direct contact with one
of the COP materials (Fig. 5). Materials 1 and 2 showed good
adherence and growth of human keratinocytes [Fig. 5(A)]
and unchanged morphology compared to controls on
FIGURE 4. Eluates from COP materials did not upregulate inflammatory adhesion molecules in human endothelial or epithelial cells. Plots show sur-
face expression of inflammatory adhesion molecules E-Selectin and ICAM-1 as well as MHC class I molecules HLA-A/B/C. Endothelial cells (A) and
epithelial cells (B) were incubated with eluates from material, medium control or TNFα for 6 hours, 24 hours, or 48 hours. Cells were gated to aquire
5000 viable cells per condition. Results are shown for COP 1 (light orange), COP 2 (orange), COP 3 (dark orange), Medium (green), and TNF (red).
Unstained cells and IgG controls are shown in blue.
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standard tissue culture plastic (data not shown). Differentia-
tion and barrier forming properties were assessed by stain-
ing keratinocyte monolayers for E-cadherin, an important
cell–cell-adhesion protein and a marker for intact epithelial
barrier formation. Materials 1 and 2 supported keratinocyte
growth and E-cadherin expression, whereas material 3 did
not [Fig. 5(B) and Supporting Information movies S2 and
S3]. Therefore COP 3 should be tested further before using it
as a material for the fabrication of long-term medical devices
applied in direct contact with the human epidermis. Notably,
COP eluates did not lead to changes in E-cadherin expression
[Supporting Information Fig. S1(D)].
FIGURE 5. Differences in cell–cell barrier and EMT markers in human keratinocytes after incubation in direct contact with COP materials. (A) Cells
were seeded on top of microneedle arrays in direct contact with the material and observed by brightfield microscopy at indicated time points.
(B) After 14 days cells were stained with Alexa-488 labeled E-cadherin Antibody (cell–cell contacts—green) and DAPI (cell nuclei—blue). HaCaT cells
seeded on top of material three showed less E-cadherin expression after 14 days in culture. White arrow marks keratinocytes without E-cadherin
expression. Green arrow marks E-cadherin positive keratinocytes on needle tip with limited contact to COP 3. Representative 3D images of three
independent experiments are shown. X-axis and Y-axis equal 600 μm, Z-axis equals 350 μm. (C) HaCaT cells seeded on top of COP 3 showed
increased expression of EMT marker vimentin after 14 days in culture. Cells were seeded on top of microneedles in direct contact with the material.
After 14 days cells were stained with directly labeled vimentin antibody and vimentin positive area per total cell area was quantified for three high
power fields per condition. Mean +/-SD n = 3.
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In keratinocytes loss of E-cadherin can be a marker for
epithelial to mesenchymal transition (EMT), a hallmark of
many adverse events, for example, during inflammation,
wound healing or cancer progression. Therefore, we also
assessed the expression of vimentin, another marker for
EMT. COP eluates did not lead to increased vimentin expres-
sion after 7 days in culture [Supporting Information Fig. S1
(E)]. Likewise, material 2 which was established as a suitable
material in all previous tests showed low to no expression of
the EMT marker vimentin in direct contact and was thus
confirmed to be suitable for the fabrication of microneedle
devices. In contrast, material 3 which already tested inferior
in E-cadherin expression, also showed increased levels of
vimentin expression, which implies greater caution for the
use of this material for medical device production [Fig. 5(C)].
DISCUSSION
The biocompatibility of COPs is commonly tested by assessing
cell morphology of fibroblasts after incubation with COP elu-
ates. However, longer application of medical devices on the
epidermis warrants additional testing of relevant cell types
that are in contact with the device material.18,19 Since the ban
on animal testing for cosmetic products in the EU, there has
been an increasing effort to develop and validate in vitro
assays for testing skin sensitization potential20–22 and new
procedures to replace animal testing in other fields are being
evaluated.23,24 However, to get a more complete picture of the
biocompatibility of COPs and a solid basis for material selec-
tion for the mass production of medical devices, such as
microneedles, further tests are needed. Therefore, in this
study, human endothelial and epithelial cell types were used
for biocompatibility testing with the elution method and direct
contact method as described in USP <87>16 and EU ISO
10993-517 and additional methods were applied to judge the
behaviour of human skin cells in direct contact with the COP
materials.
In this article, we firstly show that it is possible to use a
commercial injection molding process to replicate silicon
microneedles in COPs with shape and sharpness approaching
that of the original master template. Secondly, microneedle
arrays manufactured from a selection of COP materials were
tested for biocompatibility with human endothelial cells and
keratinocytes. In addition to evaluations of cell viability and
morphology, the materials were assessed for their potential
to influence cellular differentiation and barrier formation.
Materials that penetrate the skin barrier and are in direct
contact with human skin cells for long term applications
should not elicit any inflammatory response due to their sur-
face properties.25 As inflammatory markers, we have used
cellular adhesion molecules E-Selectin and ICAM-1 to assess
the potential for immune cell adhesion26,27 and human MHC
class I molecules HLA-A/B/C to see the potential for an
immunologic response.28,29 Yet, we did not see a change in
inflammatory markers, but a change in E-cadherin and
vimentin, which are markers for differentiation and epithe-
lial to mesenchymal transition. Thus, cytotoxicity testing and
monitoring of inflammatory and differentiation markers in
keratinocytes enabled the selection of promising candidate
materials for future medical device applications. COP mate-
rials 1 and 2 were biocompatible with human endothelial
and epithelial cells and could be selected for further testing
of finished microneedle devices for defined applications
in vivo. The results illustrate that elution based biocompati-
bility testing alone can paint an incomplete picture and dif-
ferentiation markers might be more suitable than markers of
inflammation to assess biocompatibility of COPs and human
skin cells. Thereby, more advanced staining techniques and
cell types specific for the application of the medical device
could improve the material selection process and replace
animal testing at an early stage in the device development
process.
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